Clinical trial SAFFRON
A phase III, randomised, Open-Label study of Savolitinib in combination with Osimertinib versus platinium-based doublet chemotherapy in participants with EGFR mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who have progressed on treatment with Osimertinib
Cancers | |
---|---|
Organ | Lung |
Trial status | Trial open for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | AstraZeneca |
EudraCT Identifier | 2021-006374-24 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05261399 |
Last update |